Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease
- PMID: 32791132
- DOI: 10.1053/j.gastro.2020.08.005
Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease
Abstract
Background & aims: Increased intestinal permeability has been associated with Crohn's disease (CD), but it is not clear whether it is a cause or result of the disease. We performed a prospective study to determine whether increased intestinal permeability is associated with future development of CD.
Methods: We assessed the intestinal permeability, measured by the urinary fractional excretion of lactulose-to-mannitol ratio (LMR) at recruitment in 1420 asymptomatic first-degree relatives (6-35 years old) of patients with CD (collected from 2008 through 2015). Participants were then followed up for a diagnosis of CD from 2008 to 2017, with a median follow-up time of 7.8 years. We analyzed data from 50 participants who developed CD after a median of 2.7 years during the study period, along with 1370 individuals who remained asymptomatic until October 2017. We used the Cox proportional hazards model to evaluate time-related risk of CD based on the baseline LMR.
Results: An abnormal LMR (>0.03) was associated with a diagnosis of CD during the follow-up period (hazard ratio, 3.03; 95% CI, 1.64-5.63; P = 3.97 × 10-4). This association remained significant even when the test was performed more than 3 years before the diagnosis of CD (hazard ratio, 1.62; 95% CI, 1.051-2.50; P = .029).
Conclusions: Increased intestinal permeability is associated with later development of CD; these findings support a model in which altered intestinal barrier function contributes to pathogenesis. Abnormal gut barrier function might serve as a biomarker for risk of CD onset.
Keywords: Crohn’s Risk; FDR Study; Gut Barrier; IBD.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Environmental Factors Associated With Risk of Crohn's Disease Development in the Crohn's and Colitis Canada - Genetic, Environmental, Microbial Project.Clin Gastroenterol Hepatol. 2024 Sep;22(9):1889-1897.e12. doi: 10.1016/j.cgh.2024.03.049. Epub 2024 May 16. Clin Gastroenterol Hepatol. 2024. PMID: 38759825
-
Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease.World J Gastroenterol. 2008 Mar 7;14(9):1399-405. doi: 10.3748/wjg.14.1399. World J Gastroenterol. 2008. PMID: 18322955 Free PMC article.
-
Increased Intestinal Permeability in Relatives of Patients With Crohn's Disease Is Not Associated With Small Bowel Ulcerations.Clin Gastroenterol Hepatol. 2017 Sep;15(9):1413-1418.e1. doi: 10.1016/j.cgh.2017.02.028. Epub 2017 Mar 7. Clin Gastroenterol Hepatol. 2017. PMID: 28286191
-
Review article: Intestinal permeability in Crohn's disease.Aliment Pharmacol Ther. 1997 Dec;11 Suppl 3:47-53; discussion 53-6. doi: 10.1111/j.1365-2036.1997.tb00808.x. Aliment Pharmacol Ther. 1997. PMID: 9467978 Review.
-
Intestinal permeability as a clinical surrogate endpoint in the development of future Crohn's disease therapies.Recent Pat Inflamm Allergy Drug Discov. 2010 Jun;4(2):159-76. doi: 10.2174/187221310791163080. Recent Pat Inflamm Allergy Drug Discov. 2010. PMID: 20377517 Review.
Cited by
-
Camptothecin multifunctional nanoparticles effectively achieve a balance between the efficacy of breast cancer treatment and the preservation of intestinal homeostasis.Bioact Mater. 2024 Aug 1;41:413-426. doi: 10.1016/j.bioactmat.2024.07.032. eCollection 2024 Nov. Bioact Mater. 2024. PMID: 39184827 Free PMC article.
-
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis.Gastroenterology. 2023 Apr;164(4):619-629. doi: 10.1053/j.gastro.2022.12.042. Epub 2023 Jan 10. Gastroenterology. 2023. PMID: 36634824 Free PMC article.
-
Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study.Am J Gastroenterol. 2024 Feb 1;119(2):313-322. doi: 10.14309/ajg.0000000000002502. Epub 2023 Oct 9. Am J Gastroenterol. 2024. PMID: 37721310 Free PMC article.
-
Perfluorooctanesulfonic acid modulates barrier function and systemic T-cell homeostasis during intestinal inflammation.Dis Model Mech. 2021 Dec 1;14(12):dmm049104. doi: 10.1242/dmm.049104. Epub 2021 Dec 23. Dis Model Mech. 2021. PMID: 34792120 Free PMC article.
-
Medication-Wide Study: Exploring Medication Use 10 Years Before a Diagnosis of Inflammatory Bowel Disease.Am J Gastroenterol. 2023 Dec 1;118(12):2220-2229. doi: 10.14309/ajg.0000000000002399. Epub 2023 Jul 7. Am J Gastroenterol. 2023. PMID: 37410928 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
